EANS-News: Epigenomics AG / Epigenomics AG: Dr. Uwe Staub Appointed to the Executive Board

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Board of Directors (Appointments and Changes)

Berlin, Germany, and U.S.A. (euro adhoc) - Epigenomics AG (Frankfurt
Prime Standard: ECX), the German-American cancer molecular
diagnostics company, today announced that Dr. Uwe Staub, Chief
Operating Officer (COO) of the Company, has been appointed to the
Executive Board, effective April 1, 2013. He will join the board as a
second member next to Dr. Thomas Taapken, acting CEO and CFO of
Epigenomics.

Uwe Staub joined Epigenomics in November 2008 as Senior Vice
President for Product Development and was promoted to COO in
September 2012, when his duties were expanded to now encompass R&D,
Medical and Regulatory Affairs, Customer Support and Manufacturing.
He joined the Company with 14 years experience in the IVD industry in
different positions in R&D and QA/RA at Abbott Diagnostics, Digene
and Qiagen. He holds a Ph.D. in biochemistry from the University of
Würzburg, Germany.

On his appointment Uwe Staub commented: "During recent months the
Epigenomics team has achieved extremely important milestones for the
future of the Company. I am honored by the appointment and look
forward to help guide the Company through the next phases of its
development."

"I welcome Uwe as a new member of the Executive Board. The
developments in the Company over the last months have been very
encouraging and exciting. I am extremely pleased to work with Uwe and
the entire Epigenomics team in order to achieve our shared vision of
developing Epigenomics into a commercial success story," added Thomas
Taapken, acting CEO and CFO.

Heino von Prondzynski, Chairman of the Supervisory Board, said: "Dr.
Staub has been instrumental in the successful development of
Epigenomics' products. Under his responsibility, the Company has made
significant progress towards regulatory approval of Epi proColon® in
the US for this convenient blood-based colorectal cancer screening
assay. Given his accomplishments and experience we are convinced he
is the ideal candidate to further strengthen our Executive Board."
-Ends-

Contact Epigenomics AG
Antje Zeise
Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel +49 (0) 30 24345 386
{ir@epigenomics.com}[HYPERLINK: mailto:ir@epigenomics.com]
{www.epigenomics.com}[HYPERLINK: http://www.epigenomics.com/]

For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway
Rockville, Maryland 20850
{pr@epigenomics.com}[HYPERLINK: mailto:pr@epigenomics.com]

About Epigenomics

Epigenomics ({www.epigenomics.com}[HYPERLINK:
http://www.epigenomics.com]) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through partnerships with
leading diagnostic companies and testing laboratories. Epigenomics is
an international company with operations in Europe and the U.S.A.

Epigenomics' legal disclaimers.

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the U.S.A. have
not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English